#her2 — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #her2, aggregated by home.social.
-
Advanced gallbladder cancer, HER2+++
After months in the hospital, my father finally received zanidatamab.
We had followed this drug on DengYueMed for over a year.The timing was cruel. The fever reaction was strong.
But today, he felt better, ate more, and asked for dinner.Sometimes hope isn’t a response rate.
Sometimes it’s simply getting through the day.#CancerCare #HER2 #GallbladderCancer #Caregiver #Zanidatamab #DengYueMed
-
DATE: November 20, 2025 at 05:00PM
SOURCE: BioWorld MedTechDirect article link at end of text block below.
.@Bayer #HER2-mutated #lungcancer treatment gets @FDADeviceInfo nod
Here are any URLs found in the article text:
Articles can be found by scrolling down the page at https://www.bioworld.com/topics/85-bioworld-medtech .
-------------------------------------------------
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
.
NYU Information for Practice puts out 400-500 good quality health-related research posts per week but its too much for many people, so that bot is limited to just subscribers. You can read it or subscribe at @PsychResearchBot
.
Since 1991 The National Psychologist has focused on keeping practicing psychologists current with news, information and items of interest. Check them out for more free articles, resources, and subscription information: https://www.nationalpsychologist.com
.
EMAIL DAILY DIGEST OF RSS FEEDS -- SUBSCRIBE:
http://subscribe-article-digests.clinicians-exchange.org
.
READ ONLINE: http://read-the-rss-mega-archive.clinicians-exchange.org
.
It's primitive... but it works... mostly...
.
-------------------------------------------------#healthcare #healthtech #healthcaretech #healthtechnology #medgadget #medicine #doctor #hospital #medtech
-
DATE: August 25, 2025 at 04:10PM
SOURCE: BioWorld MedTechDirect article link at end of text block below.
Aivis’ Qanti IHC uses AI to visualize biomarkers in cancer care
#medtech #cancer #HER2 #biomarker #deal #AI
Here are any URLs found in the article text:
Articles can be found by scrolling down the page at https://www.bioworld.com/topics/85-bioworld-medtech .
-------------------------------------------------
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
.
NYU Information for Practice puts out 400-500 good quality health-related research posts per week but its too much for many people, so that bot is limited to just subscribers. You can read it or subscribe at @PsychResearchBot
.
Since 1991 The National Psychologist has focused on keeping practicing psychologists current with news, information and items of interest. Check them out for more free articles, resources, and subscription information: https://www.nationalpsychologist.com
.
EMAIL DAILY DIGEST OF RSS FEEDS -- SUBSCRIBE:
http://subscribe-article-digests.clinicians-exchange.org
.
READ ONLINE: http://read-the-rss-mega-archive.clinicians-exchange.org
.
It's primitive... but it works... mostly...
.
-------------------------------------------------#healthcare #healthtech #healthcaretech #healthtechnology #medgadget #medicine #doctor #hospital #medtech
-
A recently developed ⭐️#cancer #vaccine for dogs⭐️ is showing promising results in clinical trials, which have been running since 2016, and there's hope that some of the benefits of the vaccine could be translated into human cancer treatments.
More than 300 dogs have been treated with the vaccine to date, and the twelve--month survival rate for canines with certain cancers has been lifted from about 35 percent to 60 percent. Tumors in many of the animals have also shrunk.
Known officially as the #Canine #EGFR/#HER2 #Peptide #Cancer #Immunotherapeutic, the treatment grew out of studies of autoimmune diseases, where the immune system damages the body's own tissue rather than any invading threats.
The vaccine is designed to get the immune system to attack cancer instead.In many ways tumors are like the targets of autoimmune diseases," says rheumatologist #Mark #Mamula, from the Yale University School of Medicine.
"Cancer cells are your own tissue and are attacked by the immune system. The difference is we want the immune system to attack a tumor."
As outlined in a 2021 study by Mamula and colleagues, the treatment gets the immune cells to produce antibody defenses, which attach themselves to tumors and interfere with their growth patterns.
Specifically, these antibodies hunt down two proteins: 🔸epidermal growth factor receptor 🔸( #EGFR ) and 🔸human epidermal growth factor receptor 2🔸 ( #HER2 ).
Mutations causing overexpression of these proteins drive uncontrolled cell division in some human and canine cancers.
-
"In the last 20 years, numerous other HER2-targeted therapies have proven successful in the metastatic, adjuvant and neoadjuvant settings, including another monoclonal antibody — pertuzumab — three separate tyrosine kinase inhibitors — lapatinib, neratinib, and tucatinib — and two antibody drug conjugates (ADCs) — ado-trastuzumab emtansine (T-DM1) and fam-trastuzumab deruxtecan (TDx-D)."
-
Webinar: “Identifying HER2-low expression – A pathologist led slide review”
Dr Jim Richter (Roche Diagnostics)
December 14 at 2 pm ET / 11 am PT.
https://thepathologist.videomarketingplatform.co/identifying-her2-low-expression-aHosted by The Pathologist, this event aims to highlight the importance of each level of #HER2 expression. This is supported by an image review and case scoring session for both select and difficult cases.
#breastcancer